Answers are grounded in this paper and cite their sources.
Squalamine is a steroid-polyamine conjugate compound with anti-angiogenic activity.Based on scientific ground work, it started its journey as a potential drug to treat several pathologies including age-related macular degeneration in the mid-1990s.After an odyssey of more than 20 years and clinical trials for neovascular macular degeneration with both systemic and topical application of the compound, by not succeeding in the Phase III trials as of 2018, this journey seems to have reached an end.
No takes yet. Share an insight, caveat, or question.
Tura et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: